{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-032826","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.109879+00:00","generated_at":"2026-05-26T05:54:27.822645+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Atea Pharmaceuticals appoints Arthur Kirsch to Board of Directors","bullets":["Arthur Kirsch, age 73, elected as Class I director effective February 20, 2025.","Kirsch brings experience as Senior Advisor at Alvarez & Marsal Life Sciences Industry Group.","Annual cash retainer of $45,000 plus initial option to purchase 164,800 shares vesting over 36 months.","Kirsch currently serves on board of Liquidia Technologies (LQDA); previously on boards of Kadmon, Immunomedics, POZEN, Aralez.","Compensation follows Non-Employee Director Compensation Program disclosed in Q2 2024 Form 10-Q."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-032826","json":"https://secwatch.observer/filing/0001193125-25-032826.json","markdown":"https://secwatch.observer/filing/0001193125-25-032826.md","text":"https://secwatch.observer/filing/0001193125-25-032826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525032826/0001193125-25-032826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525032826/d918567d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T05:54:27.822645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"927924c707","claim":"Arthur Kirsch was elected as Class I director at Atea Pharmaceuticals, Inc..","evidence_excerpt":"On February 20, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Atea Pharmaceuticals, Inc. (the “Company”) elected Arthur Kirsch as a Class I director of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593899/000119312525032826/0001193125-25-032826-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}